



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

**#52050**

**Date:** March 02, 2023

**Subject:** Albireo Pharma, Inc. - Cash Settlement/Acceleration of Expirations  
Option Symbol: ALBO  
Date: 03/03/2023

On March 1, 2023, Anemone Acquisition Corp., a wholly owned subsidiary of Ipsen Biopharmaceuticals, Inc., completed its tender offer for Albireo Pharma, Inc. (ALBO). The subsequent merger was consummated on March 2, 2023. As a result, each existing ALBO Common Share will be converted into the right to receive \$42.00 net cash plus one non-transferable Contingent Value Right (CVR) per share.

NOTE: The CVR represents a non-transferable contractual right to receive an additional payment as described in the offer. ALBO options will not be adjusted to call for the delivery of the CVRs.

#### **Contract Adjustment**

**Date:** March 3, 2023

**New Deliverable**  
**Per Contract:** \$4,200.00 Cash (\$42.00 x 100)

Settlement in ALBO options will take place through OCC's cash settlement system. Settlement will be accomplished by payment of the difference between the extended strike amount and the cash deliverable.

#### **Acceleration of Expirations**

Pursuant to OCC Rule 807, equity stock option contracts whose deliverables are adjusted to call for cash-only delivery will be subject to an acceleration of the expiration dates for outstanding option series. (See OCC Information Memo 23707) Additionally, the exercise by exception (ex by ex) threshold for expiring series will be \$.01 in all account types.

All series of Albireo Pharma, Inc. options whose expiration dates are after 03-17-2023 will have their expiration dates advanced to 03-17-2023. Expiration dates occurring before 03-17-2023 (e.g., Flex options) will remain unchanged.

All Albireo Pharma, Inc. options will utilize a \$.01 exercise threshold.

Option Symbol: ALBO  
Existing Expiration: All months  
New expiration date: 03-17-2023

Existing American-style Albireo Pharma, Inc. options remain exercisable at the option of the holder prior to their expiration. Exercised options will continue to settle in two business days.

### **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).